[Book Release] Value-Based Drug Pricing Guide on Flawed $500 Billion Industry Available for Preorder

The Right Price by Peter Neumann, ScD, Joshua Cohen, PhD, and Daniel Ollendorf, PhD, is available for preorder. It will be released on May 1^st. Dr. Peter Neumann serves as Director of CEVR (the Center for the Evaluation of Value and Risk in Health) at Tufts Medical Center with Dr. Joshua Cohen as Deputy Director of CEVR and Dr. Daniel Ollendorf as Director of Value Measurement and Global Health Initiatives at CEVR. The authors draw on their collective backgrounds, including Dr. Ollenforf’s role as ICER’s Chief Scientific Officer and Dr. Neumann’s role on the Congressional Budget Office’s health policy advisory board, to clearly explain the challenges facing industries directly and indirectly related to the prescription drug market, prescription drug pricing, and mechanisms used to assess value. They also propose solutions.

According to the authors, “The Right Price sheds light on the controversial topic of drug pricing by providing an accessible guide on pharmaceutical markets and analytic techniques used to measure the value of drug therapies. It illustrates the need for value-based pricing through real-life stories of patients and their experiences with the drug industry, and explains why simple solutions like price controls and the importation of cheaper drugs from other countries will not work.” They further note, “With unique industry insights and clear narrative, The Right Price unveils why the pricing of drugs continues to be so challenging and how public and private officials can create more informed policies to achieve the right balance between drug pricing and value.” Read more here.

(Source: Oxford University Press, 2021)